Rifaximin
- Generic Name
- Rifaximin
- Brand Names
- Xifaxan, Zaxine
- Drug Type
- Small Molecule
- Chemical Formula
- C43H51N3O11
- CAS Number
- 80621-81-4
- Unique Ingredient Identifier
- L36O5T016N
- Background
Rifaximin is a semisynthetic, rifamycin-based non-systemic antibiotic, meaning that the drug will not pass the gastrointestinal wall into the circulation as is common for other types of orally administered antibiotics. It has multiple indications and is used in treatment of traveller's diarrhea caused by E. coli; reduction in risk of overt hepatic encephalop...
- Indication
Rifaximin has multiple indications by the FDA: for the treatment of patients (≥12 years of age) with traveller's diarrhea caused by noninvasive strains of Escherichia coli; for the reduction of overt hepatic encephalopathy recurrence in patients ≥18 years of age; and in May 2015 it was approved for irritable bowel syndrome with diarrhea (IBS-D) treatment in ...
- Associated Conditions
- Bacterial Infections, Clostridium difficile infection recurrence, Hepatic Encephalopathy (HE), Irritable Bowel Syndrome (IBS), Traveler's Diarrhea
- Associated Therapies
- -
Rifaximin 3 Times/Day (TID) for Non-Constipation Irritable Bowel Syndrome (IBS)
- Conditions
- Interventions
- First Posted Date
- 2008-07-29
- Last Posted Date
- 2019-11-29
- Lead Sponsor
- Bausch Health Americas, Inc.
- Target Recruit Count
- 637
- Registration Number
- NCT00724126
Safety and Tolerability Study of Rifaximin in Participants With a History of Hepatic Encephalopathy
- First Posted Date
- 2008-05-30
- Last Posted Date
- 2019-08-14
- Lead Sponsor
- Bausch Health Americas, Inc.
- Target Recruit Count
- 322
- Registration Number
- NCT00686920
Gulf War Digestive Health Study
- Conditions
- Interventions
- First Posted Date
- 2008-05-20
- Last Posted Date
- 2014-08-29
- Lead Sponsor
- US Department of Veterans Affairs
- Target Recruit Count
- 54
- Registration Number
- NCT00680836
- Locations
- 🇺🇸
Division of Epidemiology, Salt Lake City, Utah, United States
Is Chronic Abdominal Pain in Pediatric Patients Due to Small Intestinal Bacterial Overgrowth?
- Conditions
- Interventions
- First Posted Date
- 2008-02-21
- Last Posted Date
- 2017-02-16
- Lead Sponsor
- Children's Hospital Los Angeles
- Target Recruit Count
- 115
- Registration Number
- NCT00619970
- Locations
- 🇺🇸
Childrens Hospital Los Angeles, Los Angeles, California, United States
Induction of Clinical Response Using Rifaximin in Crohn's Disease
- First Posted Date
- 2008-01-29
- Last Posted Date
- 2021-12-09
- Lead Sponsor
- Scott Lee
- Target Recruit Count
- 36
- Registration Number
- NCT00603616
- Locations
- 🇺🇸
University of Washington Medical Center, Seattle, Washington, United States
Transit Time and Bacterial Overgrowth Using SmartPill Capsule
- Conditions
- Interventions
- First Posted Date
- 2007-12-20
- Last Posted Date
- 2012-10-05
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 17
- Registration Number
- NCT00577772
- Locations
- 🇺🇸
Mayo Clinic Arizona, Scottsdale, Arizona, United States
Rifaximin in Minimal Hepatic Encephalopathy
- First Posted Date
- 2007-09-24
- Last Posted Date
- 2020-12-17
- Target Recruit Count
- 42
- Registration Number
- NCT00533910
- Locations
- 🇺🇸
Hunter Holmes McGuire VA Medical Center, Richmond, Virginia, United States
RICE Trial: Rifaximin In Chronic Hepatic Encephalopathy - A Randomized, Controlled Trial
- Conditions
- Interventions
- First Posted Date
- 2006-08-16
- Last Posted Date
- 2019-09-17
- Lead Sponsor
- University of Miami
- Target Recruit Count
- 13
- Registration Number
- NCT00364689
- Locations
- 🇺🇸
Center For Liver Diseases - University of Miami, Miami, Florida, United States
Antibiotics for the Treatment of Ulcerative Colitis
- Conditions
- First Posted Date
- 2006-07-24
- Last Posted Date
- 2009-02-11
- Lead Sponsor
- University of Dundee
- Target Recruit Count
- 40
- Registration Number
- NCT00355602
- Locations
- 🇬🇧
Ninewells Hospital and Medical School, Dundee, Angus, United Kingdom
Prevention of Travelers' Diarrhea in Subjects Traveling Outside the U.S.
- Conditions
- First Posted Date
- 2006-05-19
- Last Posted Date
- 2019-11-25
- Lead Sponsor
- Bausch Health Americas, Inc.
- Target Recruit Count
- 660
- Registration Number
- NCT00328380
- Locations
- 🇺🇸
Southwest Doctors, PA, Houston, Texas, United States
🇺🇸Sunshine Medical Center, South Miami, Florida, United States
🇺🇸La Porte Family Clinic, La Porte, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.